Naperville, IL -- (SBWIRE) -- 05/16/2012 -- The Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 2011–2015. One of the key factors contributing to this market growth is the increasing prevalence of hepatitis C infection. The Global Hepatitis C Drugs market has also been witnessing the shift of treatments from multiple drug therapy to single drug therapy. However, the virus developing resistance to the drugs could pose a challenge to the growth of this market.
The Global Hepatitis C Drugs Market 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis C Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Merck & Co. Inc., Roche Holding Ltd., and Vertex Pharmaceuticals Ltd.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
To view the detailed table of contents for this report please visit: